Lovenox
Lovenox is a low molecular weight heparin (LMWH) anticoagulant. It works by accelerating the inhibition of activated factor X (Factor Xa) and thrombin (Factor IIa) to prevent the formation and propagation of blood clots.
Dosage by Body Weight
Standard adult prophylaxis is typically 30 mg subcutaneously every 12 hours or 40 mg once daily. For therapeutic treatment of DVT/PE, the adult dose is typically 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily. Dosage adjustments are required for severe renal impairment. Pediatric dosing is highly specialized, requiring monitoring of anti-Xa levels.
- Body Weight
- Below 5 kg
- Dose
- 1.5 mg/kg
- Frequency
- Every 12 hours
- Tracking Notes
- Neonates (<2 months) often require higher doses (up to 1.5 to 2.0 mg/kg) to achieve therapeutic anti-Xa levels. Strict supervision by a pediatric specialist and anti-Xa monitoring are mandatory.
- Body Weight
- 5-7 kg
- Dose
- 1.0 to 1.5 mg/kg
- Frequency
- Every 12 hours
- Tracking Notes
- For therapeutic anticoagulation. Dose must be adjusted based on peak anti-Xa levels (target 0.5 to 1.0 IU/mL) measured 4 hours post-injection.
- Body Weight
- 8-10 kg
- Dose
- 1.0 mg/kg (8 - 10 mg)
- Frequency
- Every 12 hours
- Tracking Notes
- For therapeutic dosing. Prophylactic dose is typically lower (0.5 mg/kg every 12 hours or once daily). Use tuberculin or low-volume syringes for precise measurement.
- Body Weight
- 11-15 kg
- Dose
- 1.0 mg/kg (11 - 15 mg)
- Frequency
- Every 12 hours
- Tracking Notes
- Administer subcutaneously in the anterolateral or posterolateral abdominal wall. Rotate injection sites daily.
- Body Weight
- 16-20 kg
- Dose
- 1.0 mg/kg (16 - 20 mg)
- Frequency
- Every 12 hours
- Tracking Notes
- Requires regular monitoring of renal function and platelet counts in addition to anti-Xa level monitoring.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 1.5 mg/kg | Every 12 hours | Neonates (<2 months) often require higher doses (up to 1.5 to 2.0 mg/kg) to achieve therapeutic anti-Xa levels. Strict supervision by a pediatric specialist and anti-Xa monitoring are mandatory. |
| 5-7 kg | 1.0 to 1.5 mg/kg | Every 12 hours | For therapeutic anticoagulation. Dose must be adjusted based on peak anti-Xa levels (target 0.5 to 1.0 IU/mL) measured 4 hours post-injection. |
| 8-10 kg | 1.0 mg/kg (8 - 10 mg) | Every 12 hours | For therapeutic dosing. Prophylactic dose is typically lower (0.5 mg/kg every 12 hours or once daily). Use tuberculin or low-volume syringes for precise measurement. |
| 11-15 kg | 1.0 mg/kg (11 - 15 mg) | Every 12 hours | Administer subcutaneously in the anterolateral or posterolateral abdominal wall. Rotate injection sites daily. |
| 16-20 kg | 1.0 mg/kg (16 - 20 mg) | Every 12 hours | Requires regular monitoring of renal function and platelet counts in addition to anti-Xa level monitoring. |
Formulation
Purpose
Prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and management of acute coronary syndromes (unstable angina and myocardial infarction).
Generic Name
Enoxaparin sodiumScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.